MGMT PROMOTER HYPERMETHYLATION AND P53 IMMUNOHISTOCHEMISTRY PREDICT OUTCOME FOLLOWING TEMOZOLOMIDE FOR RECURRENT 1P/19Q NON-DELETED ANAPLASTIC (OLIGO)ASTROCYTOMA